Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3087 Comments
882 Likes
1
Lashaon
Active Contributor
2 hours ago
I read this and now I’m thinking in circles.
👍 111
Reply
2
Shalante
Legendary User
5 hours ago
I read this and now I feel like I missed it.
👍 55
Reply
3
Jaggyr
Registered User
1 day ago
I didn’t know humans could do this. 🤷♂️
👍 292
Reply
4
Alvia
Senior Contributor
1 day ago
I don’t get it, but I respect it.
👍 83
Reply
5
Sylia
Trusted Reader
2 days ago
Who else is going through this?
👍 194
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.